Clemex concludes a strategic alliance with RAL Diagnostics

MONTREAL, Aug. 16, 2011 /CNW/ -- 
The alliance based on a Share Swap between the two Corporations licenses
 
European market distribution of the new Clemex system for Haematology
 applications 


Symbol: CXG.A-TSX-V 
www.clemex.com
Shares Outstanding:  20,749,810


MONTREAL, Aug. 16, 2011 /CNW Telbec/ - Clemex Technologies Inc. (TSXV:
 CXG.A) announces it has concluded a strategic alliance with its
 European partner RAL Diagnostics located in Martillac, France, to
 notably support the marketing of its new instrument being developed for
 the Haematology sector. According to the partnership signed between the
 two Corporations, RAL will immediately become the exclusive distributor
 of the new microscopy instruments developed by Clemex for haematology
 and other life sciences applications in Europe.


Clemex, on the other hand, developed its new instrument for haematology
 to primarily use the new MCDH stain solution created by RAL and will
 also engage in working to develop new microscopy instruments in the
 future using the various staining solutions created and manufactured by
 RAL.


A commercial partnership in Europe


Furthermore, RAL Diagnostic immediately becomes dealer of other image
 analysis products manufactured by Clemex for all other microscopy
 applications in France, Belgium and Switzerland. Finally, RAL will
 become the privileged business partner of Clemex products for all of
 Europe within a year, and will eventually become in charge of all
 commercial activities such as distribution and marketing for all of
 Europe. With such an important partner, Clemex, which was only
 partially present in Europe, will strengthen its presence and should
 increase its sales significantly to reach North America sales levels in
 the near future.


Business transaction


After completion of this transaction, which is subject to approval by
 the regulated authorities, Clemex will hold 10% of RAL Diagnostics
 share capital. They will obtain in return 3 250 000 voting shares which
 will be issued by Clemex, representing 13.5% of all outstanding voting
 shares issued by the Company. RAL Diagnostics, which already held 750
 000 shares from a private placement concluded in 2008, will then hold,
 16.7% of the outstanding voting shares of Clemex.


At the time of signing this historic and unprecedented agreement, the
 president and CEO of Clemex Technologies declared:" We are very pleased
 to finally sign this partnership, which brings a new momentum to the
 work collaboration already set in place between the two Companies. We
 have been working with RAL for a number of years and had began the
 development of this new haematology instrument with some exchange of
 trade secret information and technologies in anticipation of this
 partnership. We had also been seeking different ways to improve our
 presence in Europe on a permanent basis for years, and this partnership
 is the perfect opportunity to realize this objective, at very low cost
 for Clemex.  RAL Diagnostics will also increase its sales with the
 distribution of our products in Europe. This partnership becomes a
 win-win situation for both parties. Furthermore, the swap of shares
 between the two companies demonstrates mutual commitment to develop the
 European market and to work together towards developing various
 competitive and distinct image analysis instruments."


For its part, the president and CEO of RAL Diagnostics, Frédéric Imbs
 added:" We are absolutely delighted about signing this partnership
 which can only have positive financial fallback for us on average term.
 We have absolute trust in Clemex's expertise and in their ability to
 develop innovative image analysis instruments. We are convinced that
 this strategic alliance between the two companies will be synergetic
 and a carrier for both parties. One must know and understand that an
 image analysis system, even highly-performing, cannot detect uncoloured
 blood smear slides, or any other tissue slide. That's where the
 knowledge of RAL Diagnostics will intervene, as we have developed
 world-class staining solutions for these applications. Our products
 will allow Clemex's image analysis systems to perform even better and
 therefore help in the most complex and sophisticated needs of the
 market today, notably in the haematology sector. There is no doubt that
 this partnership will be profitable for both companies, and this, on
 both sides of the Atlantic."


About RAL Diagnostics


RAL Diagnostics is a manufacturer of biological stains intended for the
 field of human and animal health, scientific research, medical
 diagnosis, and industry. These stains are available in liquids or ready
 to use kits. RAL Diagnostics serves 6,000 medical analysis laboratories
 and anatomopathology laboratories of France thanks to a network of 35
 distributors and 180 representatives. The company is present in more
 than 40 countries in the world.


About Clemex Technologies, Inc.


Clemex Technologies Inc. develops, manufactures and markets image
 analysis systems and software used by quality control and research
 microscopy laboratories.  Clemex customer base spans over many
 countries in America, Europe, Asia and encompasses major Research and
 Development Centers, prestigious Universities and large manufacturing
 industries in various fields including healthcare, automotive,
 aerospace, raw materials manufacturing, pharmaceuticals, mining and
 other sectors.


The TSX Venture Exchange has not reviewed and does not accept
 responsibility for the adequacy and accuracy of this news release.


To view this news release in HTML formatting, please use the following URL: http://www.cnw.ca/en/releases/archive/August2011/16/c4093.html



p bCLEMEX TECHNOLOGIES INC,/bb /bbr/ 800 Guimond,br/ Longueuil, QC, Canada J4G 1T5, /p p Contact: /p p align="justify" Clément Forgetbr/ Tel: [phone]br/ Email: a href="mailto:[e-mail]" cr="true"[e-mail]/a /p 

Copyright